Sugi Predict

Sugi Predict / Targets / CD40

CD40

Tumor necrosis factor receptor superfamily member 5 · P25942 · CD40 on Sugi Atlas →

4,381 patent compounds predicted against CD40, 2,920 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3297268 SCHEMBL3297268 0.64 3/20
SCHEMBL6242038 SCHEMBL6242038 0.61 3/20
SCHEMBL2183888 SCHEMBL2183888 0.51 3/20
SCHEMBL2189511 SCHEMBL2189511 0.51 3/20
SCHEMBL6210682 SCHEMBL6210682 0.49 3/20
SCHEMBL6363338 SCHEMBL6363338 0.48 3/20
SCHEMBL6214268 SCHEMBL6214268 0.48 3/20
SCHEMBL6208823 SCHEMBL6208823 0.46 3/20
SCHEMBL6911279 SCHEMBL6911279 0.45 3/20
SCHEMBL6210121 SCHEMBL6210121 0.43 3/20
SCHEMBL6209628 SCHEMBL6209628 0.42 3/20
SCHEMBL7522280 SCHEMBL7522280 0.41 3/20
SCHEMBL4958843 SCHEMBL4958843 0.40 3/20
SCHEMBL4958851 SCHEMBL4958851 0.40 3/20
SCHEMBL1340222 SCHEMBL1340222 0.62 2/20
SCHEMBL7224470 SCHEMBL7224470 0.59 2/20
SCHEMBL10398604 SCHEMBL10398604 0.59 2/20
SCHEMBL10413972 SCHEMBL10413972 0.57 2/20
SCHEMBL9333689 SCHEMBL9333689 0.53 2/20
SCHEMBL9058846 SCHEMBL9058846 0.52 2/20

Clinical trials — most relevant to CD40 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes PHASE4COMPLETED
Belatacept 3 Month Post Transplant Conversion Study PHASE4COMPLETED
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease PHASE3RECRUITING
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) PHASE2COMPLETED
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer PHASE2RECRUITING
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma PHASE1/PHASE2RECRUITING
Etanercept in Hidradenitis Suppurativa PHASE2COMPLETED
BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis PHASE2COMPLETED
Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction PHASE2COMPLETED
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma PHASE1/PHASE2UNKNOWN
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors PHASE1/PHASE2COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients PHASE1/PHASE2COMPLETED
Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) PHASE2COMPLETED
Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors PHASE1COMPLETED
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells PHASE1COMPLETED
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment PHASE1RECRUITING
Presurgical Trial of Denosumab in Breast Cancer EARLY_PHASE1COMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions nanCOMPLETED
Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection nanRECRUITING
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab nanNOT_YET_RECRUITING
TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) nanNOT_YET_RECRUITING
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA nanCOMPLETED
Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation nanCOMPLETED
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study nanCOMPLETED
DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CD40 binder may also engage these)

ProteinNameSimilarity
Q3LRP1 — 1.000 Q3LRP1 →
Q8SQ34 — 0.999 Q8SQ34 →
Q3ZTK5 — 0.994 Q3ZTK5 →
Q28203 — 0.992 Q28203 →
Q7YRL5 — 0.989 Q7YRL5 →
Q92956 — 0.985 Q92956 →
Q80WM9 — 0.985 Q80WM9 →
P27512 — 0.981 P27512 →
P15725 — 0.976 P15725 →
P47741 — 0.969 P47741 →
P43489 — 0.966 P43489 →
P18519 — 0.965 P18519 →
P50555 — 0.964 P50555 →
P41272 — 0.963 P41272 →
TNFRSF9 Tumor necrosis factor receptor superfamily member 9 0.963 landscape →
TNFRSF1A Tumor necrosis factor receptor superfamily member 1A 0.963 landscape →
P07174 — 0.960 P07174 →
O19131 — 0.960 O19131 →
P25118 — 0.959 P25118 →
P26842 — 0.956 P26842 →
Q9Z0W1 — 0.954 Q9Z0W1 →
P22934 — 0.952 P22934 →
Q8BX35 — 0.951 Q8BX35 →
P20333 — 0.951 P20333 →
Q9HAV5 — 0.951 Q9HAV5 →
NGFR Tumor necrosis factor receptor superfamily member 16 0.948 landscape →
P25445 — 0.948 P25445 →
Q5VV43 — 0.946 Q5VV43 →
Q9JLL3 — 0.946 Q9JLL3 →
O77736 — 0.946 O77736 →